To highlight critical advances achieved over the last year in the study of endogenous proatherogenic danger signals and corresponding molecular mechanism of innate immune signalling in atherosclerosis.
Introduction
Atherosclerosis is an inflammatory disease with a strong involvement of innate immunity. It relies on a set of pattern-recognition receptors (PRRs) for detection and clearance of harmful material and included among these are Toll-like receptors (TLRs) and cytoplasmic Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs). These groups of receptor recognize diverse molecular structures called pathogen-associated molecular patterns (PAMPs), ranging from lipids and proteins to nucleic acids that are common to many micro-organisms. Tissue damage can also trigger a process termed sterile inflammation, which was originally proposed by Matzinger [1] almost two decades ago. Her 'Danger model' indicates that endogenous damage-associated molecular patterns (DAMPs) created during tissue injury can alert our bodies' defences of an impending danger by activating the PRRs in the absence of pathogens. Some DAMPs are intracellular molecules that are released into the extracellular milieu as a result of necrosis and become danger signals that activate immune cells and vascular endothelium. Others include degradation products of extracellular matrix (ECM) or molecules that are upregulated or accumulating during an inflammatory condition. In the context of atherosclerosis, a growing body of evidence infers modified LDL as the primary DAMP. In this review we give an overview of the currently known DAMPs involved in proatherogenic processes and discuss their impact on atherosclerosis.
Activation of Toll-like receptors by tissue-derived products
TLRs are the best-characterized PRRs of the innate immune system. So far, 10 human and 13 mouse TLRs have been described and found to recognize a broad spectrum of both pathogenic structures and endogenous tissue-derived ligands. The receptors are differentially distributed within the cell with TLR1, TLR2, TLR4, TLR5 and TLR6 located on the cell surface and TLR3, TLR7, TLR8, and TLR9 expressed in intracellular compartments, such as endosomes, lysosomes and endoplasmic reticulum (ER). In humans, most TLRs can be found in the normal vessel wall and several TLRs have increased expression in atherosclerotic lesions in which they can be identified on macrophages, endothelial cells and smooth muscle cells [2-4] and can contribute to local TLR-driven responses.
Several lines of evidence have identified oxidized LDL (oxLDL) as an endogenous TLR ligand. However, the level of cell activation it induces is relatively modest and several magnitudes lower than after TLR ligation with pathogenic products [5, 6] . LDL that is minimally modified by oxidation (mmLDL) induces TLR4 and TLR2 activation in macrophages leading to cytokine production and generation of reactive oxygen species, and with TLR4 these effects seem to be mediated through different signalling pathways [5,7-10]. Furthermore, TLR4 signalling is also required for the induction of macrophage actin polymerization and macrophage spreading by oxLDL [10] , suggesting that it promotes cell migration. These processes are likely mediated through the kinase IRAK4, which has an essential role in TLR-mediated signalling and was shown in a recent study to be required for modified LDL induced nuclear factor (NF)-kB activation and expression of proinflammatory genes in macrophages [11] . Another recent study has addressed the involvement of TLRs in contributing to oxLDL-induced calcification within the plaque [6]. Vascular calcification is a common complication in atherosclerosis and an indicator of plaque instability. The process is actively regulated by osteogenic factors such as bone morphogenetic proteins (BMPs) locally expressed in blood vessels. BMP-2 is expressed in calcified human atherosclerotic plaques and Su et al.
[6] now show that stimulation by oxLDL induces BMP-2 expression through TLR2 and TLR4 in human coronary artery endothelial cells.
Interestingly, the detection of oxLDL by TLRs appears to be mediated in combination with scavenger receptors. TLR4 was shown to cooperate with TLR6 and the scavenger receptor CD36 to mediate chemokine expression induced by oxLDL [12 ] , which is the first report of these receptors acting together. In contrast, CD36 is instead partnered with TLR2 in induction of apoptosis in ER-stressed macrophages triggered by oxLDL, along with oxidized phospholipids (oxPL) saturated fatty acids (SFAs), and lipoprotein (a) [13 ] . Aside from contributing to scavenger receptor-mediated uptake, ligation of TLR4 by the endogenous ligand mmLDL, and its active components cholesteryl ester hydroperoxides, can also induce TLR4-dependent fluid phase lipid uptake that is typical of macropinocytosis [14] . In addition to excessive accumulation of lipids by tissue macrophages, this TLR4-dependent fluid phase uptake of lipoproteins can occur even in the circulation by peripheral blood monocytes under hyperlipidemic conditions [14] . Thus, monocytes already enriched in lipids prior to migration into the lesion could be more susceptible to further lipid uptake or exhibit altered metabolic properties.
Given that oxLDL is a complex structure that contains a mixture of possible ligands, including apolipoproteins, cholesterols, and phospholipids, it is difficult to determine the exact ligand that mediates receptor binding. It is also problematic to control for the level of modification to LDL and it is therefore not surprising that the effect of stimulation with oxLDL and the proposed receptors that are utilized varies between different studies. Certain components that can be found in LDL have, however, been shown to induce proatherogenic events via the TLR signalling pathway. oxPL products promote vascular inflammation and the major bioactive lipids in mmLDL are derived from oxidized products of 1-palmitoyl-2arachidonoyl-sn-glycero-3-phosphorylcholine (oxPAPC), which mediate their activation through TLR4 [15] . However, certain oxPAPC phospholipids also have inhibitory properties on TLR4 and TLR2 inflammatory signalling, further complicating the story [16, 17] . Although not an element of LDL, ApoCIII, a component of very lowdensity lipoprotein (VLDL), is recognized by TLR2 and triggers proinflammatory signals that lead to increased adhesion of monocytes to endothelial cells [18] [19] [20] . It has also been proposed that dietary SFAs may serve as endogenous ligands of TLR2 or TLR4, thereby linking dietary fat intake with disease [21,22]. However, these findings were recently challenged because lipopolysaccharide (LPS) and lipopeptide contaminations were reported in the carrier used to complex the SFAs [23].
Other described endogenous ligands that are most likely released from necrotic cells are heat shock proteins and they are also shown to induce the production of proinflammatory cytokines using a TLR2 and TLR4-dependent pathway [24] [25] [26] [27] [28] [29] . Furthermore, several host-specific nucleic acids are recognized by TLRs, including mRNA by TLR3 [30] and RNA/DNA by TLR7 and TLR9 [31] [32] [33] , which are also likely to be found in the necrotic core. Recently, the ubiquitously expressed regulator of microtubule formation stathmin was also found to be an endogenous activator of TLR3, and might impact on atherosclerosis if released during cell death [34] . [35] [36] [37] [38] [39] [40] [41] [42] [43] . All of these are present in the plaque and EDA levels in the lesion have correspondingly been shown to accumulate with disease progression in Apoe À/À mice and promote lesion development [44, 45] . However, key endogenous ligands of TLR in atherosclerosis remain an enigma (Table 1) .
Effect of Toll-like receptor deficiency in hyperlipidemic mice: in-vivo role in sterile inflammation
Perhaps the strongest evidence indicating that TLRs play a role in sterile inflammation comes from studies in proatherosclerotic mouse models in which knockouts of specific TLRs affect disease development. TLR2 and TLR4 have both been found to promote atherosclerotic progression in hyperlipidemic mouse models, in the absence of infection or exogenous ligands [46] [47] [48] [49] . A recent study investigated the role of TLR3 in atherosclerosis [50] . TLR3-deficient hyperlipidemic Apoe À/À mice exhibited a modest increase in atherosclerosis at early stages when compared with controls [50] . However, there was no difference in macrophage infiltration in the TLR3-deficient Apoe À/À mice and no mechanism was proposed that could explain this result. Furthermore, the observed effect on lesion growth was lost at more advanced stages of the disease [50] . This proposes that TLR3 through an unknown mechanism might have a protective role on lesion development in hyperlipidemic mice, at least during early stages of the disease. Additional investigations will be necessary to clarify the puzzling role described for TLR3 in atherosclerosis.
Signalling molecules downstream of the TLRs are also involved in this process and mice deficient in either the adaptor protein MyD88 or the kinase IRAK4 exhibited marked reduction in lesion size in Apoe À/À mice [11, 46, 51, 52] . However, aside from being involved in TLR activation, these signalling molecules are also crucial for signalling via the IL-1 and IL-18 receptors and the observed effects could, therefore, be due to an inhibition of these receptors, particularly because IL-1/IL-18 stimulation has been shown to promote atherosclerosis [53] [54] [55] .
Although several of the TLRs and their signalling pathways have been shown to control atherogenic processes induced by endogenous DAMPs in vivo, the exact ligand responsible for mediating these effects are yet to be identified.
Identification of cholesterol crystals as a danger signal that activates NOD-like receptors inflammasome in atherosclerosis
In contrast to TLRs that are membrane-bound receptors, the NLR proteins are cytoplasmic pathogen PRRs, which resemble in structure to a subgroup of plant disease resistance (R) genes. There are more than 20 NLR genes found so far in humans. The family of NLR can be categorized in general into two major subgroups on the Innate immunity and inflammation in atherosclerosis Lundberg and Yan 345 basis of N-terminal effector domain: the caspase recruitment domains (CARD)-containing NLRC group and the pyrin domain containing NLRP group. A prominent feature of NLRP is the assembly of a caspase-1 activating multiprotein complex, so-called 'inflammasome', when triggered by PAMPs or DAMPs. NLRP3 inflammasome represents the best-studied example among NLRs. It is composed of a NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and the inflammation-associated protease caspase-1 [56] . Formation of NLRP3 inflammasome results in activation of caspase-1 and maturation of IL-1b and IL-18 [57] . Currently, NLRP3 inflammasome draws intense attention in the field of atherosclerosis research as recent observations reporting that cholesterol crystals functioning as endogenous danger signal trigger NLRP3 inflammasome, and that NLRP3 inflammasome signaling promotes the disease progression [58 ,59 ,60 ] .
IL-1b is a potent proatherogenic cytokine [61] . However, a long-standing question has been what signalling mechanism instigates IL-1b production in atherosclerosis. Recent researches, both in vitro and in vivo, consistently point to the fact that cholesterol crystals are bioactive danger signals. When assessing NLRP3 inflammasome signalling in atherosclerosis, two studies found that cholesterol crystal formation is an early process that is associated with recruitment of inflammatory cells in atherosclerotic lesion, and that incubation of LPS-primed macrophages with cholesterol crystals resulted in activation of caspase-1 and generation of mature IL-1b, the two hallmarks of inflammasome activation [58 ,62] . In contrast, the inflammasome was activated in the crystal-treated macrophages from NLRP3-deficient mice, proving that cholesterol crystals are NLRP3-dependent activator of inflammasome [58 ,62] . Importantly, cholesterol crystals-induced activation of NLRP3 inflammasome could be replicated in human macrophages [60 ] . But, it is unlikely that cholesterol crystal is the sole activator of NLRP3 in atherosclerosis. Supporting data from another recent study suggest that 7-ketocholesterol, a common derivative of LDL oxidation, is also able to trigger caspase-1 activation in an NLRP3dependent manner [59 ] .
A challenge to the knowledge of NLRP3 inflammasome activation in atherosclerosis is how NLRP3 could sense, or in another word, be activated by cholesterol crystals. Currently, three models, referred to as the Kþ efflux, the lysosome damage, and the reactive oxygen species model, are proposed to explain the activation of NLRP3 in response to an expanding list of PAMPs and DAMPs [56] . Recent studies on cholesterol crystal-induced NLRP3 activation lend support to the second model that phagocytozed cholesterol crystals cause phagolysosomal membrane rupture, resulting in the release of lysosomal protease, such as cathepsin B, as the effector in NLRP3 activation, given pharmacological inhibition of cathepsin or genetic depletion of cathepsins reduce the ability of cholesterol crystal to induce IL-1b production [58 ,60 ] . A caveat of lysosomal damage model is that it does not explain all types of NLRP3 activator, and does not explain how the released proteases activate NLRP3 inflammasome. Several critical observations recently shed light in favour that mitochondrial reactive oxygen species (ROS) operates as a common mechanism converging and instructing the activation of NLRP3 in response to diversified NLRP3 activators, including recently suggested high glucose levels in b cells [63] , palmitate [64] islet amyloid polypeptide [65] , ceramide and undefined obesity-associated danger signal [66, 67] .
Freigang et al. [62] recently found that cholesterol crystal activates transcription factor NF-E2-related 2 (NRF2), an oxidation responsive transcription factor that regulates expression of various antioxidant and detoxification enzymes, and that activation of NLRP3 by cholesterol crystals is impaired in the cells with NRF2 deficiency. This observation hints the relevance of the mitochondrial ROS model to cholesterol crystal-induced activation of NLPR3. Importantly, the mitochondrial ROS model illustrates a potential link between oxidative stress, inflammation and chronic inflammatory diseases.
Role of nucleating receptor protein3 inflammasome in atherosclerosis
A potential role for inflammasome vascular diseases was recently suggested by Yajima et al. [68] . Using a mouse vascular injury model, they found that expression of ASC, the central adaptor protein of inflammasome complex, was upregulated in association with increased IL-1b and IL-18 in the site of vascular injury. Genetic depletion of ASC in bone marrow cells resulted in reduced generation of active IL-1a and neointimal formation. These findings reveal a crucial role of inflammasome in the process of vascular repair. But, this proof-of-concept study clarified neither the vascular injury-derived danger signal that activates the inflammasome nor specific NLR that participates in inflammasome activation.
With establishing cholesterol crystal as the danger signal of NLRP3 activation, Duewell et al. [58 ] determined the importance of NLRP3 inflammasome and the downstream effector IL-1b to atherosclerosis using LDL receptordeficient mice, an established model of experimental atherosclerosis. The chimeric mice with NLRP3-deficient bone marrow were associated with significantly reduced plasma level of IL-18, an inflammasome-dependent cytokine, and notably, 69% reduction in atherosclerotic lesion size at aortic sinus compared with the mice transferred with the wild-type bone marrow. Likewise, the mice reconstituted with ASC or IL-1-deficient bone marrow were also found with drastic reduction of atherosclerotic lesion.
These data indicate NLRP3 inflammasome of myeloid cells as a key contributor to the development of atherosclerosis. However, it is noteworthy that discordant results are reported by another recent study based on the model of global deletion of NLRP3, ASC, or caspase-1 in atherosclerosis-prone Apoe À/À mice [59 ] . Precise explanations for the divergence between the two studies remain to be clarified. Nonetheless, neither study provides information whether NLRP3 or ASC deficiency indeed alters mature IL-1b at the site of atherosclerotic lesion. As Apoe À/À mice lacking IL-1b [53] , or MyD88 [51] , which is required for TLR-induced upregulation of IL-1b expression and for downstream signalling of IL-1b receptor, renders protection against atherosclerosis, these observations argue for a detrimental role for NLRP3 inflammasome in atherosclerosis. Furthermore, a most recent study shows that inflammasomes are induced and activated in the infiltrated macrophages and neutrophils in ischemic myocardium and in cardiac fibroblasts in response to ischemia/reperfusion injury, contributing to production of IL-1b and development of myocardial infarction [69] . Together, these findings establish a broad implication of inflammasome in the pathogenesis of cardiovascular diseases. It is of great interest whether NLRP3 inflammasome and IL-1b signalling could be translated as targets of therapy for atherosclerosis. But, a crucial issue to be clarified is the relevance of experimental understandings of NLRP3 inflammasome to human atherosclerosis. In this regard, Abela et al. [70] reported recently that the current most effective medicine of atherosclerosis, statins inhibit in a direct manner cholesterol crystals in vivo, although it is still unclear if this effect of statins is correlated with alteration in inflammasome activity and IL-1b production.
Conclusion
There is considerable evidence in support of a link between atherosclerosis progress and modified LDL instigated inflammatory responses. Studies of LDLderived bioactive components have revealed phospholipids and cholesterol crystals as danger signals that trigger oxidative stress, inflammatory responses via activation of TLR and NLRP3 inflammasome pathways, respectively. But, LDL particles may also yield additional proteinbased DAMPs rather than the defined lipid derivatives, given the observation that atherosclerosis develops strong antibody responses against certain ApoB fragments [71] . These recent findings provide new avenues for understanding of the aetiology and therapy for atherosclerosis, a current global pandemic.
